Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
Capitalization 19.21B 26.11B P/E ratio 2024 *
24.7x
P/E ratio 2025 * 22.2x
Enterprise value 17.09B 23.24B EV / Sales 2024 *
4.8x
EV / Sales 2025 * 4.34x
Free-Float
76.62%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.64%
1 week+0.21%
Current month+1.10%
1 month+0.96%
3 months+14.99%
6 months+7.58%
Current year+14.95%
More quotes
1 week
79.16
Extreme 79.1595
83.09
1 month
79.16
Extreme 79.1595
83.09
Current year
70.53
Extreme 70.53
84.67
1 year
64.02
Extreme 64.02
84.67
3 years
59.78
Extreme 59.78
87.88
5 years
26.49
Extreme 26.49
87.88
10 years
22.70
Extreme 22.7
87.88
More quotes
Director TitleAgeSince
Chief Executive Officer 60 13-12-06
Director of Finance/CFO 54 05-12-31
Chief Operating Officer 44 17-08-31
Manager TitleAgeSince
Director/Board Member 70 07-10-21
Director/Board Member 53 11-10-31
Director/Board Member 73 13-05-05
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.62%+0.21%+14.08%+5.80%19.21B
-0.64%-2.16%+20.28%+2.33%235B
-1.17%-0.70%+7.49%-15.94%199B
-1.38%-0.02%+62.37%+40.02%175B
-1.38%-1.35%+54.60%+84.67%123B
+1.19%-0.20%+10.45%-13.49%61.32B
-2.05%+0.09%-7.87%-43.73%41.78B
-0.29%-0.12%+22.34%-20.74%39.74B
+0.40%+1.62%+31.17% - 39.57B
-0.20%-4.31%-16.42%-29.48%39.5B
Average -0.65%+0.75%+19.85%+1.05% 97.27B
Weighted average by Cap. -0.87%+1.03%+26.64%+10.97%
See all sector performances
2024 *2025 *
Net sales 4.02B 5.47B 4.24B 5.76B
Net income 795M 1.08B 875M 1.19B
Net Debt 74.38M 101M -828M -1.13B
More financial data * Estimated data
Logo Hologic, Inc.
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Employees
6,990
More about the company
Date Price Change Volume
24-09-17 82.14 $ -0.68% 667,554
24-09-16 82.70 $ +1.91% 1,424,960
24-09-13 81.15 $ +0.91% 1,442,155
24-09-12 80.42 $ +0.51% 958,882
24-09-11 80.01 $ -2.38% 1,590,576

Delayed Quote Nasdaq, September 17, 2024 at 02:11 pm

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
82.70USD
Average target price
87.33USD
Spread / Average Target
+5.60%
Consensus
-40% Exceptional Extension: Our subscriptions help you unlock hidden opportunities. Exceptional extension!
BENEFIT NOW